Ophthalmologica Update: The Peer-reviewed Journal Of EURETINA Edited By Sebastian Woolf
Volume: 238 Issue: 4

Sebastian Wolf
Published: Wednesday, November 1, 2017
NEW CATETHER PROVIDES SAFE AND EFFECTIVE RETINAL FLUID DRAINAGE
External drainage of subretinal fluid (SRF) using a 24-G Optiva IV catheter is safe, efficient and useful in eyes with bullous exudative retinal detachment (RD), new research suggests. In a study involving 13 eyes of 13 patients with bullous exudative RD, SRF drainage was successfully accomplished in all eyes using a transconjunctival scleral incision with the 24-G catheter. Except for one case of localised subretinal haemorrhage, no complications were noted. J Peng et al, “A Modified Technique for the Transconjunctival and Sutureless External Drainage of Subretinal Fluid in Bullous Exudative Retinal Detachment Using a 24-G i.v. Catheter”, Ophthalmologica 2017, Volume 238, Issue 4.
THREE-INJECTION LOADING DOSE EXTENDS TREATMENT-FREE INTERVAL
In a study involving 61 eyes of 56 patients with myopic choroidal neovascularisation, eyes on a pro re nata (PRN) ranibizumab regimen appeared to achieve about the same visual outcomes whether they received a loading dose of three consecutive monthly injections or a loading dose of just one injection (p= 0.824). However, after a mean follow-up of 53 months, eyes that received the three-injection loading dose had a significantly longer treatment-free interval than those that received the one-injection loading dose (36.9 months vs 19.2 months; p < 0.001).
C Calvo-González et al, “Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization”, Ophthalmologica 2017, Volume 238, Issue 4.
EARLY DETECTION AND TREATMENT ACHIEVES BETTER LONG-TERM RESULTS IN NEOVASCULAR AMD
Eyes with neovascular AMD treated early in the course of their disease appear to remain responsive to anti-VEGF therapy longer than those with more advanced disease at the time treatment is initiated, according to the findings of a retrospective review study. It showed that among 67 eyes consecutively treated with more than 30 intravitreal anti-VEGF injections between 2007 and 2014, those with good final visual acuity also had better initial VA (p = 0.020) and maintained it. In contrast, patients with moderate-to-poor final VA improved significantly after the first three monthly injections, and thereafter deteriorated consistently, mostly during the third (p = 0.019) and fourth (p = 0.006) years. Patients with initially moderate-to-poor vision also had more scarring and intraretinal fluid. O.Sagiv et all, “Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections”, Ophthalmologica 2017, Volume 238, Issue 4.
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.